MVASI (bevacizumab-awwb)
MVASI is a vascular endothelial growth factor inhibitor used to treat several types of advanced, metastatic, or recurrent cancers, including colorectal, lung, glioblastoma, renal, cervical, and ovarian malignancies. It is primarily administered in combination with specific chemotherapy regimens or interferon-alfa, though it may be used as a single agent in certain maintenance or recurrent settings. The drug is indicated for various stages of treatment, such as first-line or second-line therapy, but is specifically not indicated for the adjuvant treatment of colon cancer.
How MVASI Works
MVASI works by binding to vascular endothelial growth factor (VEGF) to prevent it from interacting with its receptors on the surface of endothelial cells. This interaction normally stimulates the proliferation of endothelial cells and the formation of new blood vessels, a process known as angiogenesis. By blocking this pathway, the drug reduces microvascular growth and inhibits the progression of metastatic disease.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2017-09-14
- Revenue
- $213M (Q3-2025)
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
MVASI Approval History
What MVASI Treats
8 indicationsMVASI is approved for 8 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Metastatic Colorectal Cancer
- Non-Small Cell Lung Cancer
- Glioblastoma
- Renal Cell Carcinoma
- Cervical Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
MVASI Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
MVASI is a lower-cost alternative to Avastin with no clinically meaningful differences. Requires prescriber approval to substitute.
MVASI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in MVASI's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications MVASI treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to MVASI
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06252649 CodeBreaK 301 | 20210081 | Ph 3 | recruiting | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation |
| NCT05183984 NIRVANA-1 | GINECO-OV129b 2023-504166-37-00 | Ph 2 | recruiting | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer |
| NCT05180422 | 02AT21-KRAS | Ph 1, Ph 2 | withdrawn | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MVASI FDA Label Details
Indications & Usage
FDA Label (PDF)MVASI is indicated for the treatment of Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer.
Pro Intelligence Preview
Deep insights for MVASI
Revenue Insights
- • Q3-2025: $213M
- • Historical trend analysis
Patent Timeline
- • Patent expiration dates
- • Generic/biosimilar risk
Trial Analysis
- • 3 total trials
- • Stage: Growth
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment